A major drawback in Alzheimer’s disease (AD) is the lack of validated biomarkers for routine clinical diagnostic. We have reported earlier a novel blood biomarker, named Alz-tau®, based on variants of platelet tau. This marker evaluates the ratio of high molecular weight tau (HMWtau) and the low molecular weight (LMWtau) tau.
Objective:
To analyze a potential novel source of antigen for Alz-tau®, plasma tau, detected by immunoreactivity with the novel monoclonal antibody, tau51.
Methods:
We evaluated tau variants in plasma precipitated with ammonium sulfate from 36 AD patients and 15 control subjects by western blot with this novel monoclonal antibody.
Results:
The HMW/LMWtau ratio was statistically different between AD patients and controls.
Conclusions:
Plasma tau variants are suitable to be considered as a novel antigen source for the Alz-tau® biomarker for AD.
HoltzmanDM, MorrisJC, GoateAM (2011) Alzheimer’s disease: the challenge of the second century. Sci Transl Med3, 77sr71.
3.
HampelH, SchneiderLS, GiacobiniE, KivipeltoM, SindiS, DuboisB, BroichK, NisticoR, AisenPS, ListaS (2015) Advances in the therapy of Alzheimer’s disease: targeting amyloid beta and tau and perspectives for the future. Expert Rev Neurother15, 83–105.
4.
HebertLE, ScherrPA, BieniasJL, BennettDA, EvansDA (2003) Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol60, 1119–1122.
5.
Martinez-CueC, RuedaN (2020) Cellular senescence in neurodegenerative diseases. Front Cell Neurosci14, 16.
6.
MaccioniRB, RojoLE, FernandezJA, KuljisRO (2009) The role of neuroimmunomodulation in Alzheimer’s disease. Ann N Y Acad Sci1153, 240–246.
7.
MoralesI, FariasG, MaccioniRB (2010) Neuroimmunomodulation in the pathogenesis of Alzheimer’s disease. Neuroimmunomodulation17, 202–204.
8.
JayapalanS, NatarajanJ (2013) The role of CDK5 and GSK3B kinases in hyperphosphorylation of microtubule associated protein tau (MAPT) in Alzheimer’s disease. Bioinformation9, 1023–1030.
9.
MoralesI, JimenezJM, MancillaM, MaccioniRB (2013) Tau oligomers and fibrils induce activation of microglial cells. J Alzheimers Dis37, 849–856.
ThancharoenO, LimwattananonC, WaleekhachonloetO, RattanachotphanitT, LimwattananonP, LimpawattanaP (2019) Ginkgo biloba extract (EGb761), cholinesterase inhibitors, and memantine for the treatment of mild-to-moderate Alzheimer’s disease: a network meta-analysis. Drugs Aging36, 435–452.
12.
AtriA (2019) Current and future treatments in Alzheimer’s disease. Semin Neurol39, 227–240.
13.
RitchieC, SmailagicN, Noel-StorrAH, UkoumunneO, LaddsEC, MartinS (2017) CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev3, CD010803.
14.
de SouzaLC, ChupinM, LamariF, JardelC, LeclercqD, ColliotO, LehericyS, DuboisB, SarazinM (2012) CSF tau markers are correlated with hippocampal volume in Alzheimer’s disease. Neurobiol Aging33, 1253–1257.
15.
ZhangS, SmailagicN, HydeC, Noel-StorrAH, TakwoingiY, McShaneR, FengJ (2014) (11)C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst RevCD010386.
16.
MartinezG, VernooijRW, Fuentes PadillaP, ZamoraJ, FlickerL, BonfillCosp X (2017) 18F PET with florbetaben for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev11, CD012883.
17.
SchmandB, HuizengaHM, vanGool WA (2010) Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer’s disease. Psychol Med40, 135–145.
KoyamaA, OkerekeOI, YangT, BlackerD, SelkoeDJ, GrodsteinF (2012) Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol69, 824–831.
20.
TatebeH, KasaiT, OhmichiT, KishiY, KakeyaT, WaragaiM, KondoM, AllsopD, TokudaT (2017) Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome. Mol Neurodegener12, 63.
21.
KandimallaR, ManczakM, YinX, WangR, ReddyPH (2018) Hippocampal phosphorylated tau induced cognitive decline, dendritic spine loss and mitochondrial abnormalities in a mouse model of Alzheimer’s disease. Hum Mol Genet27, 30–40.
22.
Guzman-MartinezL, FariasGA, MaccioniRB (2013) Tau oligomers as potential targets for Alzheimer’s diagnosis and novel drugs. Front Neurol4, 167.
23.
NeumannK, FariasG, SlachevskyA, PerezP, MaccioniRB (2011) Human platelets tau: a potential peripheral marker for Alzheimer’s disease. J Alzheimers Dis25, 103–109.
24.
Guzman-MartinezL, TapiaJP, FariasGA, GonzalezA, EstrellaM, MaccioniRB (2019) The Alz-tau biomarker for Alzheimer’s disease: study in a Caucasian population. J Alzheimers Dis67, 1181–1186.
25.
FariasG, PerezP, SlachevskyA, MaccioniRB (2012) Platelet tau pattern correlates with cognitive status in Alzheimer’s disease. J Alzheimers Dis31, 65–69.
26.
SlachevskyA, Guzman-MartinezL, DelgadoC, ReyesP, FariasGA, Munoz-NeiraC, BravoE, FariasM, FloresP, GarridoC, BeckerJT, LopezOL, MaccioniRB (2017) Tau platelets correlate with regional brain atrophy in patients with Alzheimer’s disease. J Alzheimers Dis55, 1595–1603.
